Open Accessopical mycophenolate mofetil in the treatment of vitiligo: a pilot study
Author(s) -
Farhad Handjani,
Shahin Aghaei,
Iman Moezzi,
Nasrin Saki
Publication year - 2017
Publication title -
dermatology practical and conceptual
Language(s) - English
Resource type - Journals
ISSN - 2160-9381
DOI - 10.5826/dpc.0702a06
Subject(s) - vitiligo , medicine , mycophenolate , dermatology , autoimmune hepatitis , psoriasis , autoimmune disease , disease , hepatitis , immunology , surgery , transplantation
Vitiligo is a multifactorial disease that is characterized by circumscribed depigmented macules and patches. Autoimmune reactions may play an important role in the pathogenesis of the disease. Mycophenolate mofetil is a drug that inhibits DNA synthesis in lymphocytes and has been used in autoimmune diseases such as immunobullous skin diseases, lupus erythematosus, and autoimmune hepatitis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom